Clinical Research Directory

Eligibility Criteria \*\*Inclusion Criteria\*\* 1. Age ≥ 18 years 2. Renal biopsy consistent with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) confirmed by central pathologic review 3. 24-hour urine protein ≥ 1 g on two occasions ≥ 4 weeks apart while receiving optimal renin-angiotensin system blockade (ACEi or ARB at maximal tolerated dose) 4. Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m² calculated by CKD-EPI equation 5. Willing and able to provide written informed consent and comply with all study procedures \*\*Exclusion Criteria\*\* 1. Rapidly progressive glomerulonephritis or crescentic disease (\>50 % crescents) 2. Known malignant hematologic disorders (e.g., multiple myeloma, lymphoma) 3. Active malignancy (except adequately treated basal-cell carcinoma) within 5 years 4. Neutrophil count \< 1.0 × 10⁹/L, hemoglobin \< 80 g/L, or platelet count \< 50 × 10⁹/L 5. ALT or AST \> 2.5 × upper limit of normal (ULN) or total bilirubin \> 1.5 × ULN 6. Chronic obstructive pulmonary disease (COPD) requiring systemic steroids or Stage III/IV heart failure (NYHA) 7. Systemic immunosuppressive or biologic therapy (e.g., cyclophosphamide, rituximab, bortezomib, lenalidomide, tacrolimus, mycophenolate, etc.) within 3 months prior to screening 8. Chronic or latent infection: active tuberculosis, HBV (HBsAg-positive or HBV-DNA-positive), HCV antibody-positive, or HIV-positive 9. Live vaccine within 4 weeks of screening 10. Known hypersensitivity to telitacicept or any excipients 11. Pregnancy, breastfeeding, or inadequate contraception (women of child-bearing potential and men not using highly effective contraception) 12. Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study conduct